HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.

Abstract
Despite efforts aimed at developing novel therapeutics for traumatic brain injury (TBI), no specific pharmacological agent is currently clinically available. Here, we show that the pan-histone deacetylase (HDAC) inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h postinjury. Using a well-characterized, clinically relevant mouse model of closed head injury (CHI), we demonstrate that a single dose of ITF2357 administered 24 h postinjury improves neurobehavioral recovery from d 6 up to 14 d postinjury (improved neurological score vs. vehicle; P< or =0.05), and that this functional benefit is accompanied by decreased neuronal degeneration, reduced lesion volume (22% reduction vs. vehicle; P< or =0.01), and is preceded by increased acetylated histone H3 levels and attenuation of injury-induced decreases in cytoprotective heat-shock protein 70 kDa and phosphorylated Akt. Moreover, reduced glial accumulation and activation were observed 3 d postinjury, and total p53 levels at the area of injury and caspase-3 immunoreactivity within microglia/macrophages at the trauma area were elevated, suggesting enhanced clearance of these cells via apoptosis following treatment. Hence, our findings underscore the relevance of HDAC inhibitors for ameliorating trauma-induced functional deficits and warrant consideration of applying ITF2357 for this indication.
AuthorsNa'ama A Shein, Nikolaos Grigoriadis, Alexander G Alexandrovich, Constantina Simeonidou, Athanasios Lourbopoulos, Eleni Polyzoidou, Victoria Trembovler, Paolo Mascagni, Charles A Dinarello, Esther Shohami
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 23 Issue 12 Pg. 4266-75 (Dec 2009) ISSN: 1530-6860 [Electronic] United States
PMID19723705 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Hydroxamic Acids
  • Neuroprotective Agents
  • Caspase 3
  • Histone Deacetylases
  • givinostat hydrochloride
Topics
  • Animals
  • Apoptosis (drug effects)
  • Brain (pathology)
  • Brain Injuries (drug therapy)
  • Caspase 3 (metabolism)
  • Histone Deacetylases (metabolism)
  • Hydroxamic Acids (administration & dosage, pharmacology)
  • Male
  • Mice
  • Neuroglia (drug effects)
  • Neuroprotective Agents (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: